All content on this page is intended strictly for research and educational purposes. IGF-1 LR3 and MGF (Mechano Growth Factor) are research compounds supplied for laboratory use only and are not licensed for human therapeutic use. No information here constitutes medical advice, treatment recommendations, or clinical guidance. Researchers should consult applicable regulatory frameworks before designing any study involving these compounds.
Two mechanistically distinct IGF-1 splice variants: systemic versus local muscle biology
IGF-1 LR3 (long-arginine-3 IGF-1) and MGF (Mechano Growth Factor, also termed IGF-1Ec in humans and IGF-1Eb in rodents) are both derived from the IGF1 gene but represent mechanistically distinct research tools for skeletal muscle biology. Their fundamental difference lies not in receptor selectivity — both ultimately engage the IGF-1 receptor — but in their pharmacokinetic profiles (systemic vs local), IGFBP binding characteristics, temporal action windows (sustained vs transient), and the specific phase of satellite cell biology they most effectively engage.
IGF-1 LR3 is a modified recombinant IGF-1 molecule (~9117Da, t½ ~20–30h) engineered to resist IGFBP (insulin-like growth factor binding protein) binding, providing prolonged systemic IGF-1R stimulation and sustained mTORC1-S6K1 anabolic signalling. MGF is the mechano-responsive, short-half-life (~minutes for intact MGF, ~hours for PEG-MGF) locally acting splice variant produced acutely in mechanically stressed muscle fibres through alternative splicing of the IGF1 gene exon 5 to generate a unique 24-amino acid E-peptide domain. MGF primarily activates satellite cells in a paracrine/autocrine manner, promoting their entry from quiescence into the active proliferative state before differentiation commitment.
🔗 Related Reading: For comprehensive coverage of IGF-1 LR3 research, mTOR signalling, and satellite cell biology, see our IGF-1 LR3 Pillar Guide.
IGF-1 LR3: sustained mTORC1 anabolic signalling and systemic muscle biology
The Arg³ substitution in IGF-1 LR3 reduces IGFBP-3 binding affinity approximately 100-fold compared with native IGF-1 (IGFBP-3 Ki ~3.5nM for native IGF-1 vs ~350nM for LR3), while retaining high IGF-1R binding affinity (IGF-1R Ki ~1.2nM vs ~1.0nM for native IGF-1, essentially equivalent). This IGFBP-resistance dramatically extends systemic bioavailability from IGF-1’s ~12–15 minute half-life (90% bound to IGFBP-3:ALS ternary complex in circulation) to approximately 20–30 hours for IGF-1 LR3, enabling sustained receptor occupancy at peripheral tissues including skeletal muscle.
The canonical IGF-1 LR3 signalling cascade in skeletal muscle is: IGF-1R → IRS-1 → PI3K-p110α → Akt Ser473 → mTORC1 → S6K1 Thr389 + 4EBP1 Thr37/46 → ribosomal protein synthesis augmentation. Upstream, IRS-1 acts as a signalling scaffold — its phosphorylation by the IGF-1R intrinsic tyrosine kinase on Tyr612 and Tyr632 creates SH2-domain docking sites for PI3K p85 regulatory subunit, initiating the PI3K lipid kinase activation. In skeletal muscle primary myotube cultures, IGF-1 LR3 at 10nM produces maximum pAkt Ser473 at approximately 30 minutes post-administration (approximately 2.2-fold above basal), maintained at approximately 1.7-fold above basal for 4 hours — reflecting the prolonged receptor occupancy from IGFBP-resistance. Native IGF-1 at equivalent molar concentration peaks at approximately 1.9-fold at 15 minutes then returns to baseline by 2 hours due to rapid IGFBP association.
Muscle protein synthesis (MPS) rate measured by puromycin incorporation (SUnSET assay) increases approximately 34–42% above basal under IGF-1 LR3 at 1mg/kg i.p. in rodent gastrocnemius, sustained over 6 hours post-injection. In comparison, native IGF-1 at equivalent dose produces approximately 24–28% MPS increase over 2 hours, returning to basal by 4 hours. The MPS differential reflects the pharmacokinetic advantage of LR3 in maintaining sustained mTORC1 engagement for prolonged translational augmentation.
IGF-1 LR3 also has significant systemic anti-catabolic effects through Akt-FoxO1/3a phosphorylation: FoxO1a Ser256 phosphorylation under IGF-1 LR3 increases approximately 1.6-fold in gastrocnemius, nuclear FoxO1a decreases approximately 42–48%, and atrophy genes MuRF1 and MAFbx/atrogin-1 decrease approximately 28–34% and 24–28% respectively. This anti-proteolytic mechanism operates through the same Akt pathway as MPS augmentation and represents a second anabolic contribution beyond simple ribosomal synthesis rate enhancement.
MGF (Mechano Growth Factor): acute satellite cell activation and paracrine biology
MGF (IGF-1Ec in humans, IGF-1Eb in rodents) is produced in skeletal muscle fibres within minutes of mechanical loading — specifically through a mechano-sensitive alternative splicing event that includes exon 5 of the IGF1 gene, generating a C-terminal 24-amino acid E-peptide distinct from the Ea E-peptide of mature systemic IGF-1. The mature MGF protein comprises the shared IGF-1 domain (which binds IGF-1R equivalently to systemic IGF-1) plus the unique Ec/Eb E-peptide, which is rapidly cleaved in vivo by serine proteases, releasing both the IGF-1 domain (which enters the IGF-1R signalling cascade) and the free E-peptide (which has IGF-1R-independent biological activities).
The MGF E-peptide’s primary documented activity is satellite cell activation — promoting the transition of quiescent Pax7+/MyoD− satellite cells into the active Pax7+/MyoD+ state — through a mechanism that is only partially IGF-1R-dependent. Evidence suggests the E-peptide may activate a distinct receptor or co-receptor that signals through Notch pathway components and CaMKII (calmodulin-dependent protein kinase II), promoting satellite cell self-renewal and proliferation without simultaneously committing cells to terminal differentiation. This is mechanistically distinct from the full IGF-1 LR3 signal, which promotes both satellite cell activation AND myoblast differentiation through the downstream mTORC1-MyoD cascade.
In mechanical overload models (synergist ablation, where surgical removal of gastrocnemius forces compensatory hypertrophy of the plantaris), MGF E-peptide peaks at approximately 2–4 hours post-overload stimulus in the plantaris, returning to basal within 8–12 hours. Exogenous E-peptide administration (synthetic 24-aa MGF E-peptide, 50µg/kg i.m.) at this acute window increases satellite cell activation (Pax7+/MyoD+ double-positive) approximately 38–44% above vehicle at 12 hours, with BrdU+ satellite cells increasing approximately 32–38%. Critically, MyoG+ (differentiation marker) satellite cells at 12 hours do NOT increase significantly, confirming that E-peptide promotes the proliferative expansion of the progenitor pool without committing cells to immediate differentiation.
PEG-MGF (pegylated Mechano Growth Factor) is a modified form with covalent polyethylene glycol conjugation at Lys68 of the E-peptide domain, extending the half-life from approximately 10–15 minutes (intact MGF in vivo) to approximately 4–6 hours, allowing meaningful systemic delivery without the pharmacokinetic limitation of the native peptide. PEG-MGF at 1mg/kg twice weekly in CTX muscle injury models produces satellite cell BrdU+ counts approximately 32–38% above vehicle at day 5, type IIb fibre CSA approximately 18–24% above vehicle at day 14, and grip strength approximately 14–18% above vehicle at day 21. The PEG modification eliminates the E-peptide serine protease cleavage that would normally generate free E-peptide and free IGF-1 domain separately — PEG-MGF must be considered a pharmacokinetically modified construct rather than a true physiological MGF analogue.
🔗 Related Reading: For comprehensive coverage of MGF and PEG-MGF research, mechano growth factor biology, and satellite cell activation mechanisms, see our MGF / PEG-MGF Pillar Guide.
Head-to-head mechanistic comparison: the key distinctions
The fundamental distinction between IGF-1 LR3 and MGF in muscle research can be summarised along three axes:
Temporal action window: IGF-1 LR3’s 20–30h half-life produces sustained mTORC1 engagement appropriate for prolonged anabolic stimulus research (24–72h MPS enhancement, multi-day anti-catabolic signalling). MGF’s acute E-peptide window (2–12h post-mechanical stimulus) is most relevant to the first 12 hours post-exercise or post-injury when satellite cell activation is the rate-limiting regenerative step. PEG-MGF extends this to a 4–6h window, but still substantially shorter than IGF-1 LR3.
Downstream effector targets: IGF-1 LR3 → mTORC1 → S6K1/4EBP1 → ribosomal protein synthesis (myofibre anabolism) + FoxO1a → anti-catabolism. MGF E-peptide → satellite cell CaMKII/Notch → Pax7+MyoD+ activation (progenitor cell pool expansion) without immediate differentiation commitment. These are sequential processes: MGF expands the progenitor pool; IGF-1 LR3 drives the anabolic translation programme in committed myotubes. Using IGF-1 LR3 alone without satellite cell recruitment may produce anabolism in existing fibres without adequate regenerative support for repetitive injury. Using MGF alone without sustained mTORC1 signalling in differentiating myotubes may expand the satellite cell pool without maximising myotube protein synthesis.
IGFBP and bioavailability considerations: IGF-1 LR3’s IGFBP-resistance is its defining pharmacokinetic feature — without it, exogenous IGF-1 is cleared within minutes. MGF/PEG-MGF’s E-peptide region prevents IGF-1 domain IGFBP binding through steric hindrance of the C-terminal extension, providing intrinsic IGFBP-resistance that is structurally different from LR3’s N-terminal Arg³ modification. Both compounds escape IGFBP-3:ALS ternary complex sequestration but through different structural mechanisms — IGFBP receptor competition studies can distinguish their relative bioavailability profiles in tissue-specific contexts.
Key experimental controls for mechanistic attribution
For IGF-1 LR3 research, required controls include: IGF-1R-blocking antibody (αIR3, 10µg/mL) to confirm IGF-1R-dependent mechanism; rapamycin (mTORC1 inhibitor, 10nM) to confirm mTORC1-dependent MPS contribution; FoxO1a constitutive nuclear mutant (3A-FoxO1) to confirm Akt-FoxO1a anti-catabolic contribution; and native IGF-1 at matched molar dose as the direct pharmacokinetic comparator.
For MGF/PEG-MGF research, required controls include: synthetic C-terminal E-peptide only (24-aa) to confirm E-peptide-specific satellite cell activation; synthetic N-terminal IGF-1 domain only to confirm IGF-1R contribution separately; αIR3 (IGF-1R blocker) to quantify E-peptide-independent versus IGF-1R-dependent satellite cell activation; and timing controls (E-peptide administration at 0h, 6h, 12h, 24h post-injury) to confirm the acute activation window claimed for MGF’s mechanism.
Research applications and model selection
IGF-1 LR3 is most informative in models where sustained anabolic signalling is the research question: prolonged immobilisation atrophy recovery, cancer cachexia (sustained catabolic state requiring sustained anti-catabolic mTORC1 support), sarcopenia in aged animals requiring chronic mTORC1 restoration, and anabolic resistance research where the dose-response of mTORC1 activation is the primary endpoint. IGF-1 LR3’s systemic pharmacokinetics make it well-suited to these chronic, multi-week research designs.
MGF/PEG-MGF is most informative in acute injury models where the first 12–24 hours of satellite cell activation are the mechanistic focus: CTX or BaCl₂ injection, surgical muscle trauma, or mechano-overload (synergist ablation). The E-peptide’s acute window means that administration timing relative to injury is the most critical variable, and research designs must account for this by including multiple administration timing arms (at injury, 2h post, 6h post, 24h post) to characterise the dose-timing response.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified IGF-1 LR3 and PEG-MGF for research and laboratory use. View UK stock →
Summary: IGF-1 LR3 versus MGF for muscle research
IGF-1 LR3 and MGF/PEG-MGF are mechanistically complementary research tools operating at different phases of skeletal muscle biology. IGF-1 LR3 delivers sustained (20–30h) IGFBP-resistant IGF-1R → mTORC1 → S6K1/4EBP1 anabolic signalling and FoxO1a-mediated anti-catabolism — appropriate for chronic atrophy, cachexia, and sarcopenia research requiring prolonged anabolic support. MGF E-peptide delivers acute (2–12h) satellite cell activation — Pax7+/MyoD+ proliferative expansion without premature differentiation commitment — appropriate for acute injury models where satellite cell recruitment is the rate-limiting regenerative step. A sequential research design (MGF at injury → IGF-1 LR3 at day 3–7) targeting the separate activation and anabolic phases of regeneration represents the mechanistically rational approach to testing their combined and individual contributions to skeletal muscle recovery.
